Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 2
1974 1
1976 3
1978 1
1979 2
1980 1
1981 1
1982 2
1984 1
1985 3
1987 2
1989 2
1991 1
1993 1
1994 6
1995 3
1996 3
1997 4
1998 4
1999 9
2000 6
2002 4
2003 2
2004 1
2005 4
2006 6
2007 5
2008 8
2009 5
2010 7
2011 15
2012 19
2013 15
2014 22
2015 20
2016 8
2017 13
2018 22
2019 10
2020 12
2021 10
2022 13
2023 2
Text availability
Article attribute
Article type
Publication date

Search Results

249 results
Results by year
Filters applied: . Clear all
Page 1
Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease.
Ayalon G, Lee SH, Adolfsson O, Foo-Atkins C, Atwal JK, Blendstrup M, Booler H, Bravo J, Brendza R, Brunstein F, Chan R, Chandra P, Couch JA, Datwani A, Demeule B, DiCara D, Erickson R, Ernst JA, Foreman O, He D, Hötzel I, Keeley M, Kwok MCM, Lafrance-Vanasse J, Lin H, Lu Y, Luk W, Manser P, Muhs A, Ngu H, Pfeifer A, Pihlgren M, Rao GK, Scearce-Levie K, Schauer SP, Smith WB, Solanoy H, Teng E, Wildsmith KR, Bumbaca Yadav D, Ying Y, Fuji RN, Kerchner GA. Ayalon G, et al. Among authors: teng e. Sci Transl Med. 2021 May 12;13(593):eabb2639. doi: 10.1126/scitranslmed.abb2639. Sci Transl Med. 2021. PMID: 33980574 Clinical Trial.
Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial.
Teng E, Manser PT, Pickthorn K, Brunstein F, Blendstrup M, Sanabria Bohorquez S, Wildsmith KR, Toth B, Dolton M, Ramakrishnan V, Bobbala A, Sikkes SAM, Ward M, Fuji RN, Kerchner GA; Tauriel Investigators. Teng E, et al. JAMA Neurol. 2022 Aug 1;79(8):758-767. doi: 10.1001/jamaneurol.2022.1375. JAMA Neurol. 2022. PMID: 35696185 Free PMC article. Clinical Trial.
Response to Dr. Finucane.
Teng E, Mendez MF. Teng E, et al. J Am Geriatr Soc. 2018 Apr;66(4):830-831. doi: 10.1111/jgs.15234. Epub 2018 Jan 18. J Am Geriatr Soc. 2018. PMID: 29345806 No abstract available.
Current issues in the treatment of OC-spectrum conditions.
Wetterneck CT, Teng EJ, Stanley MA. Wetterneck CT, et al. Among authors: teng ej. Bull Menninger Clin. 2010 Spring;74(2):141-66. doi: 10.1521/bumc.2010.74.2.141. Bull Menninger Clin. 2010. PMID: 20545493 Review.
Communicating mild cognitive impairment diagnoses with and without amyloid imaging.
Grill JD, Apostolova LG, Bullain S, Burns JM, Cox CG, Dick M, Hartley D, Kawas C, Kremen S, Lingler J, Lopez OL, Mapstone M, Pierce A, Rabinovici G, Roberts JS, Sajjadi SA, Teng E, Karlawish J. Grill JD, et al. Among authors: teng e. Alzheimers Res Ther. 2017 May 4;9(1):35. doi: 10.1186/s13195-017-0261-y. Alzheimers Res Ther. 2017. PMID: 28472970 Free PMC article. Review.
249 results